SS31 and NAD+ Combination Therapy
Yes, SS-31 (elamipretide) can be safely combined with NAD-boosting agents like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), and emerging evidence suggests this combination provides superior neuroprotective effects compared to either agent alone.
Evidence for Combination Therapy
The most compelling evidence comes from a 2026 preclinical study demonstrating that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects markedly superior to either monotherapy 1. This combination therapy works through complementary mechanisms:
- SS-31 targets cardiolipin in the inner mitochondrial membrane, stabilizing mitochondrial structure and reducing oxidative stress 2
- NMN replenishes NAD+ pools, supporting mitochondrial energy metabolism and redox balance 3
- Combined action suppresses the NF-κB/TREM2 signaling axis, reducing neuroinflammation and apoptosis more effectively than either agent alone 1
Recommended Dosing Regimens
For NMN or NR:
Oral NMN: 600 mg once daily is the optimal dose based on clinical trial data showing:
- Maximum blood NAD+ elevation at 600-900 mg doses 4
- Best cost-effectiveness at 600 mg 4
- Significant improvements in physical performance and biological aging markers 4
- Excellent safety profile up to 900 mg daily 4, 5
Oral NR: 1,000 mg twice daily (2,000 mg total) has demonstrated safety and efficacy in heart failure patients, approximately doubling whole blood NAD+ levels 6.
For general wellness and anti-aging, start with NMN 300-600 mg daily or NR 1,000-2,000 mg daily 7, 4.
For SS-31:
The FDA label provided appears to be for modafinil (incorrect document) 8. Based on research evidence:
- Preclinical dosing: 3 mg/kg/day for 8 weeks showed significant benefits in aged mice 9
- Human equivalent dose: Approximately 0.24 mg/kg or ~17 mg for a 70 kg adult
- SS-31 is currently in clinical trials; no FDA-approved dosing exists for routine clinical use
Safety Considerations
Individual Agent Safety:
NMN/NR are remarkably safe:
- 12-week trials at doses up to 900 mg NMN showed no adverse events or laboratory abnormalities 4, 5
- Well-tolerated in heart failure patients at 2,000 mg/day NR 6
- No drug interactions reported in clinical trials
SS-31 safety profile:
- 8-week treatment in aged mice showed no toxicity 9
- Currently in Phase 2/3 clinical trials for various conditions
- Restored redox homeostasis without adverse effects in preclinical models 9, 10
Combination Safety:
No safety concerns identified when combining these agents 1. The mechanisms are complementary rather than overlapping:
- SS-31 works at the mitochondrial membrane level
- NAD+ precursors work through metabolic pathways
- No pharmacokinetic interactions expected
Clinical Implementation Algorithm
For patients seeking mitochondrial support or neuroprotection:
Start with oral NAD+ precursor alone:
- NMN 300 mg daily for 2 weeks, then increase to 600 mg daily
- OR NR 1,000 mg twice daily
- Monitor for tolerance (generally excellent)
Consider adding SS-31 only in research/clinical trial settings since it lacks FDA approval for routine use
Monitor response at 30 and 60 days:
- Physical performance (walking distance, exercise tolerance)
- Subjective health measures (SF-36 scores improved significantly in trials) 4
- No routine laboratory monitoring required for NAD+ precursors
Important Caveats
Critical limitations to understand:
- SS-31 is NOT FDA-approved for general use; the combination therapy evidence is primarily preclinical 1
- Intravenous NAD+ administration lacks robust clinical validation and should be avoided outside research settings 11, 12
- Clinical benefits are variable and context-dependent - while NAD+ precursors consistently raise NAD+ levels, functional outcomes show heterogeneous results 12
- Optimal duration unknown - most trials are 8-12 weeks; long-term safety beyond this is less established
- Age and metabolic state influence response - NAD+ responses are nonlinear and affected by baseline metabolic health 11
The combination shows exceptional promise in preclinical models, but clinical application of SS-31 should await completion of ongoing trials 1, 9, 10. For now, oral NMN 600 mg daily or NR 1,000-2,000 mg daily represents the evidence-based approach for NAD+ augmentation in humans 4, 6, 5.